loader2
Partner With Us NRI

Company details

54.00
57.35
53.80
107.00
6M Return -7.51%
1Y Return -21.79%
Mkt Cap.(Cr) 90.24
Volume 4,810
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 4,810

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 16.13 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,081.38 -37,247.74
LAST 3M 71,111.08 -54,074.79
LAST 6M 141,746.37 -188,969.09
LAST 12M 212,995.89 -183,256.64

Information

  • About Company
  • Company Info
  • Listing Info
291.84
46.82%
10.1486
3.92%
2.49%
Description
  • Biofil Chemicals and Pharmaceuticals Ltd., headquartered in Indore, Madhya Pradesh, is engaged in the production of pharmaceuticals. The company's current market capitalisation on the Indian stock exchange is Rs. 99 crore, making it a small-cap company. The company was incorporated as a private limited company in 1985 but was converted to a public limited company in 1992.  The key members of this company are Romil Shah, Ramesh Shah, Shaila Jain, and Satish Beohar. As of the financial year 2020-21, Biofil’s net income was Rs. 1.25 crore. At present, the company is listed on both the National Stock Exchange and the Bombay Stock Exchange (BOM: 524396) and is traded under the script name BIOFILCHEM.

    Biofil Chemicals’ product portfolio includes dry syrups, injectables, and eye drops. Its product segment also includes plastic droppers and caps. Talking about Biofil’s financials, the price to book ratio of the company is 6.16, which is worse than the industry average. The same can be said for the price-to-equity ratio, which is 42.64 greater than the industry average. However, the company has seen significant growth in terms of profit and revenue. Biofil Chemicals’ net income and revenue grew at yearly rates of 21.68% and 9.89%, respectively. Both of these figures are higher than the industry average. For the last four financial years, the company’s net profit was Rs. 0.47 crore, Rs. 0.48 crore, Rs. 1.20 crore, and Rs. 1.25 crore, respectively. The earnings per share for the same period were Rs. 0.29, Rs. 0.29, Rs. 0.74, and Rs. 0.77, respectively. The company has also managed to lower its total liabilities in comparison to what it was in FY 2020. The total liabilities for the FY 2021 were 17.11 crore. Biofil’s free cash flow also reflects the positive numbers on the financial chart. 

    On April 4, 2022, Biofil Chemicals’ share price closed at Rs. 67.20, which reflects a surge of 9.98% with respect to the previous day’s closing price. During the past 12 months, the Biofil Chemicals share saw a major movement on the price chart, mostly in the downward trend. The 52-week Biofil Chemical share price high and low were recorded at Rs. 107 and Rs. 54.45, respectively.  The Biofil Chemical share is currently competing with Sun Pharmaceuticals Company Ltd., CIPLA Ltd., Dr Reddy's Laboratories Ltd., and Gland Pharma Ltd. 

    Disclaimer:- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Read More

Registered Address

11/12 Sector E Sanwer Road, Sanwer Road Industrial Area, Indore, Madhya Pradesh, 452015

Tel : 91-731-2426700
Email : bcplcompliance:gmail.com
Website : http://www.biofilgroup.net

Registrar

Ankit Consultancy Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524396
NSE Code : BIOFILCHEM
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE829A01014

ICICIdirect Biofil Chemicals & Pharmaceuticals Ltd FAQ

You can buy Biofil Chemicals & Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Biofil Chemicals & Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 27, 2022 04:01 PM the closing price of Biofil Chemicals & Pharmaceuticals Ltd was ₹ 55.45.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 27, 2022 04:01 PM, the market cap of Biofil Chemicals & Pharmaceuticals Ltd stood at ₹ 90.24.
The latest PE ratio of Biofil Chemicals & Pharmaceuticals Ltd as of May 27, 2022 04:01 PM is 291.84
The latest PB ratio of Biofil Chemicals & Pharmaceuticals Ltd as of May 27, 2022 04:01 PM is 0.18
The 52-week high of Biofil Chemicals & Pharmaceuticals Ltd is ₹ 107.00 while the 52-week low is ₹ 53.80 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE